Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).

Lansigan F, Costa CA, Zaki BI, Yen SP, Winer ES, Ryan H, Findley D, Metzler SR, Shaw L, Toaso B, MacKenzie TA, Chen Y, Beaven AW.

Clin Cancer Res. 2019 Oct 15;25(20):6073-6079. doi: 10.1158/1078-0432.CCR-18-3755. Epub 2019 Jun 26.

PMID:
31243122
2.

Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.

Moskowitz AJ, Herrera AF, Beaven AW.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:477-486. doi: 10.1200/EDBK_238799. Epub 2019 May 17.

PMID:
31099645
3.

Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.

Kelsey CR, Broadwater G, James O, Chino J, Diehl L, Beaven AW, Chang C, Koontz BF, Prosnitz LR.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):96-101. doi: 10.1016/j.ijrobp.2019.02.055. Epub 2019 Mar 8.

PMID:
30858144
4.

Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma.

Torok JA, Wu Y, Chino J, Prosnitz LR, Beaven AW, Kim GJ, Kelsey CR.

Anticancer Res. 2018 May;38(5):2875-2881.

PMID:
29715111
5.

Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.

Hudson KE, Rizzieri D, Thomas SM, LeBlanc TW, Powell Z, Diehl L, Moore JO, DeCastro C, Beaven AW.

Br J Haematol. 2019 Feb;184(4):647-650. doi: 10.1111/bjh.15138. Epub 2018 Feb 21. No abstract available.

PMID:
29468651
6.

Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging.

Song EJ, Torok J, Wu Y, Chino J, Prosnitz LR, Beaven AW, Kelsey CR.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):145-151. doi: 10.1016/j.clml.2017.12.007. Epub 2017 Dec 30.

PMID:
29358045
7.

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.

Boss MK, Dewhirst MW, Sampaio RS, Bennett A, Tovmasyan A, Berman KG, Beaven AW, Rizzieri DA, Batinic-Haberle I, Hauck ML, Spasojevic I.

Cancer Chemother Pharmacol. 2017 Aug;80(2):421-431. doi: 10.1007/s00280-017-3372-z. Epub 2017 Jul 6.

8.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

9.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

10.

Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma.

Beaven AW, Samsa G, Zimmerman S, Smith SK.

Cancer Invest. 2016 Jul 2;34(6):279-85. doi: 10.1080/07357907.2016.1194427. Epub 2016 Jul 5.

11.

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.

Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators.

Eur Heart J. 2016 Jan 21;37(4):412-22. doi: 10.1093/eurheartj/ehv611. Epub 2015 Dec 5.

12.

Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.

Beaven AW, Diehl LF.

Hematology Am Soc Hematol Educ Program. 2015;2015:550-8. doi: 10.1182/asheducation-2015.1.550.

PMID:
26637771
13.

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM.

Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2.

14.

Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.

Torok JA, Wu Y, Prosnitz LR, Kim GJ, Beaven AW, Diehl LF, Kelsey CR.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):54-9. doi: 10.1016/j.ijrobp.2015.02.003.

PMID:
25863754
15.

Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.

Boyle J, Beaven AW, Diehl LF, Prosnitz LR, Kelsey CR.

Oncology (Williston Park). 2014 Dec;28(12):1074-81, 1084.

16.

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.

Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A.

Br J Haematol. 2014 Jul;166(1):77-83. doi: 10.1111/bjh.12846. Epub 2014 Mar 25.

17.

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.

Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text.

18.

Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks.

Kelsey CR, Beaven AW, Diehl LF, Prosnitz LR.

Oncology (Williston Park). 2012 Dec;26(12):1182-9, 1193. Review.

19.

Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy.

Dorth JA, Prosnitz LR, Broadwater G, Beaven AW, Kelsey CR.

Radiat Oncol. 2012 Jun 21;7:100. doi: 10.1186/1748-717X-7-100.

20.

Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib.

Brander DM, Beaven AW.

Patient Prefer Adherence. 2012;6:239-51. doi: 10.2147/PPA.S23241. Epub 2012 Mar 23.

21.

Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.

Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):762-7. doi: 10.1016/j.ijrobp.2011.12.067. Epub 2012 Mar 13.

PMID:
22420972
22.

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.

Beaven AW, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M, Ford P, Smith J, Goy A.

Leuk Lymphoma. 2012 Feb;53(2):254-8. doi: 10.3109/10428194.2011.608445. Epub 2011 Sep 19.

PMID:
21812533
23.

Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA.

Cancer Invest. 2011 Mar;29(3):214-9. doi: 10.3109/07357907.2010.550663.

PMID:
21314330
24.

Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?

Kelsey CR, Beaven AW, Diehl LF, Prosnitz LR.

Oncology (Williston Park). 2010 Nov 30;24(13):1204-12.

25.

The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans.

Dorth JA, Chino JP, Prosnitz LR, Diehl LF, Beaven AW, Coleman RE, Kelsey CR.

Ann Oncol. 2011 Feb;22(2):405-10. doi: 10.1093/annonc/mdq389. Epub 2010 Jul 30.

PMID:
20675560
26.

Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.

Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA.

Leuk Lymphoma. 2009 May;50(5):741-8. doi: 10.1080/10428190902853136.

PMID:
19358012
27.

The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature.

Beaven AW, Shea TC.

Support Cancer Ther. 2007 Sep 1;4(4):188-97. doi: 10.3816/SCT.2007.n.014.

PMID:
18632516
28.
29.
30.

Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.

Beaven AW, Goldberg RM.

Oncology (Williston Park). 2006 Apr;20(5):461-9; discussion 469-70, 473-5. Review.

Supplemental Content

Loading ...
Support Center